Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-UMIN000005231
JPRN-UMIN000005231CompletedPhase 3

ncontrol trial of rituximab treatment on steroid dependent and frequently relapsing minimal cahnge nephrotic syndrome(MCNS) - Uncontrol trial of rituximab treatment on steroid dependent and frequently relapsing minimal cahnge nephrotic syndrome(MCNS)

Department of Medicine, Kidney Center, Tokyo Women's Medical University0 sites50 target enrollmentStarted: March 10, 2011Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
50
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 60years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •positive serology for hepatitis B and C, HIV and antinuclear antibodies, sereve renal dysfunction and liver dysfunction, pregnant woman

Investigators

Sponsor
Department of Medicine, Kidney Center, Tokyo Women's Medical University

Similar Trials

Recruiting
Not Applicable
Study on the effect of rituximab for steroid-dependent nephrotic syndromesteroid-dependent nephrotic syndrome
JPRN-UMIN000017470Graduate School Medical Sciences, Kyushu University5
Completed
Phase 3
Rituximab for Idiopathic Nephrotic SyndromeIdiopathic Nephrotic Syndrome
NCT04494438Istituto Giannina Gaslini30
Active, not recruiting
Not Applicable
Randomized controlled study of rituximab and steroid treatment in thyroid-associeted ophthalmopathy (TAO) - NDThyroid associeted ophthalmopathy.MedDRA version: 6.1Level: SOCClassification code 10015919
EUCTR2007-003910-33-ITOSPEDALE MAGGIORE DI MILANO (IRCCS)
Active, not recruiting
Not Applicable
Rituximab treatment in patients with tjyroid associated that do not respond to intravenous steroids or relapse after intravenous steroid treatmentThyroid associated opthalmopathy
EUCTR2011-000899-33-SEDepartment of Endocrinology, Sahlgrenska University Hospital50
Not yet recruiting
Phase 2
Phase II study of the addition of rituximab to dmCODOX-M/IVAC therapy for AIDS-related burkitt lymphomaAIDS-related burkitt lymphoma
JPRN-UMIN000011661ational Hospital Organization Nagoya Medical Center26